非小细胞肺癌中microRNAs与EGFR-TKIs继发性耐药机制的研究进展OA北大核心CSCDCSTPCD
Advance in MicroRNAs and EGFR-TKIs Secondary Resistance Research in Non-small Cell Lung Cancer
近年来，在非小细胞肺癌（non-small cell lung cancer, NSCLC）靶向治疗中，尤其是伴有表皮生长因子受体（epidermal growth factor receptor,EGFR）基因突变的患者，EGFR酪氨酸激酶抑制剂（tyrosine kinase inhibitor, TKI）越来越多地进入到临床治疗，但EGFR-TKI耐药的产生不仅影响药物敏感性，甚至出现疾病进展，成为制约其疗效的主要瓶颈。微小RNA（micr…查看全部>>
In recent years, in non-small cell lung cancer (NSCLC) targeted therapy, especially in patients with epidermal growth factor receptor (EGFR) mutations, EGFR-tyrosine kinase inhibitors (TKI) more and more come into the clinical treatment, but EGFR-TKI resistance not only inlfuence the drug sensitivity, appear even disease progression, become the main bottleneck of its curative effect. MicroRNAs (miRNAs) is a non coding RNA and protein involved in regulating g…查看全部>>
段晓阳;史健
050000石家庄，河北医科大学050000石家庄，河北医科大学第四医院肿瘤内科
肺肿瘤MicroRNAsEGFR-TKIs继发性耐药
Lung neoplasmsMicroRNAsEGFR-TKIsSecondary resistance
《中国肺癌杂志》 2014 (12)
860-864,5
评论